{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T+cells&page=53", "query": { "intervention": "T cells", "page": 53 }, "page_size": 10 }, "pagination": { "page": 53, "page_size": 10, "total_count": 3574, "total_pages": 358, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T+cells&page=54&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T+cells&page=52&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T19:40:18.728Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01730157", "title": "Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Ciliary Body and Choroid Melanoma, Medium/Large Size", "Ciliary Body and Choroid Melanoma, Small Size", "Extraocular Extension Melanoma", "Iris Melanoma", "Liver Metastases", "Metastatic Intraocular Melanoma", "Recurrent Intraocular Melanoma", "Stage IV Intraocular Melanoma" ], "interventions": [ { "name": "ipilimumab", "type": "BIOLOGICAL" }, { "name": "yttrium Y 90 glass microspheres", "type": "RADIATION" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2012-12", "completion_date": "2016-02", "has_results": false, "last_update_posted_date": "2016-03-10", "last_synced_at": "2026-11-15T19:40:18.728Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01730157" }, { "nct_id": "NCT03453801", "title": "The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza", "Healthy" ], "interventions": [ { "name": "Fluzone®", "type": "BIOLOGICAL" }, { "name": "FluMist®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Months", "maximum_age": "10 Years", "sex": "ALL", "summary": "6 Months to 10 Years" }, "enrollment_count": 80, "start_date": "2014-09-30", "completion_date": "2019-01-14", "has_results": false, "last_update_posted_date": "2020-02-13", "last_synced_at": "2026-11-15T19:40:18.728Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03453801" }, { "nct_id": "NCT01307618", "title": "Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IV Skin Melanoma" ], "interventions": [ { "name": "NA17.A2 Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "Recombinant MAGE-3.1 Antigen", "type": "BIOLOGICAL" }, { "name": "Recombinant Interleukin-12", "type": "BIOLOGICAL" }, { "name": "MART-1 Antigen", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2011-02", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2016-10-24", "last_synced_at": "2026-11-15T19:40:18.728Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01307618" }, { "nct_id": "NCT05079282", "title": "Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory T Cell Lymphoma" ], "interventions": [ { "name": "ONO-4685", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ono Pharmaceutical Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 217, "start_date": "2021-12-10", "completion_date": "2028-08-31", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-11-15T19:40:18.728Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Duarte, California • Orange, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05079282" }, { "nct_id": "NCT03866382", "title": "Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Adenocarcinoma", "Bladder Clear Cell Adenocarcinoma", "Bladder Mixed Adenocarcinoma", "Bladder Neuroendocrine Carcinoma", "Bladder Small Cell Neuroendocrine Carcinoma", "Bladder Squamous Cell Carcinoma", "Chromophobe Renal Cell Carcinoma", "Collecting Duct Carcinoma", "Invasive Bladder Giant Cell Urothelial Carcinoma", "Invasive Bladder Lymphoepithelioma-Like Carcinoma", "Invasive Bladder Nested Urothelial Carcinoma", "Invasive Bladder Plasmacytoid Urothelial Carcinoma", "Invasive Bladder Sarcomatoid Urothelial Carcinoma", "Invasive Bladder Urothelial Carcinoma", "Kidney Medullary Carcinoma", "Large Cell Neuroendocrine Carcinoma", "Malignant Testicular Leydig Cell Tumor", "Malignant Testicular Sertoli Cell Tumor", "Metastatic Bladder Carcinoma", "Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma", "Metastatic Bladder Giant Cell Urothelial Carcinoma", "Metastatic Bladder Large Cell Neuroendocrine Carcinoma", "Metastatic Bladder Lipid-Rich Urothelial Carcinoma", "Metastatic Bladder Micropapillary Urothelial Carcinoma", "Metastatic Bladder Plasmacytoid Urothelial Carcinoma", "Metastatic Bladder Sarcomatoid Urothelial Carcinoma", "Metastatic Bladder Small Cell Neuroendocrine Carcinoma", "Metastatic Bladder Squamous Cell Carcinoma", "Metastatic Chromophobe Renal Cell Carcinoma", "Metastatic Kidney Medullary Carcinoma", "Metastatic Malignant Genitourinary System Neoplasm", "Metastatic Papillary Renal Cell Carcinoma", "Metastatic Penile Carcinoma", "Metastatic Prostate Small Cell Neuroendocrine Carcinoma", "Metastatic Sarcomatoid Renal Cell Carcinoma", "Metastatic Urethral Carcinoma", "Papillary Renal Cell Carcinoma", "Sarcomatoid Renal Cell Carcinoma", "Stage IV Bladder Cancer AJCC v8", "Stage IV Penile Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8", "Urachal Adenocarcinoma", "Urethral Clear Cell Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2019-05-13", "completion_date": "2027-02-28", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-15T19:40:18.728Z", "location_count": 581, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 376 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03866382" }, { "nct_id": "NCT07224373", "title": "An Open-label Study of AZD0120 in Adults With Multiple Sclerosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "AZD0120 - Regimen 1", "type": "BIOLOGICAL" }, { "name": "AZD0120 - Regimen 2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 24, "start_date": "2025-12-09", "completion_date": "2028-12-12", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-11-15T19:40:18.728Z", "location_count": 9, "location_summary": "Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07224373" }, { "nct_id": "NCT04502446", "title": "A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "T Cell Lymphoma" ], "interventions": [ { "name": "CTX130", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "CRISPR Therapeutics AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2020-07-31", "completion_date": "2024-08-30", "has_results": false, "last_update_posted_date": "2025-01-08", "last_synced_at": "2026-11-15T19:40:18.728Z", "location_count": 8, "location_summary": "Duarte, California • Stanford, California • New Haven, Connecticut + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04502446" }, { "nct_id": "NCT03239470", "title": "Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pemphigus Foliaceus", "Pemphigus Vulgaris" ], "interventions": [ { "name": "Cohort 1: 1.0 x 10^8 PolyTregs", "type": "BIOLOGICAL" }, { "name": "Cohort 2: 2.5x10^8 PolyTregs", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 5, "start_date": "2017-10-10", "completion_date": "2023-01-09", "has_results": true, "last_update_posted_date": "2024-02-15", "last_synced_at": "2026-11-15T19:40:18.728Z", "location_count": 4, "location_summary": "San Francisco, California • Iowa City, Iowa • Durham, North Carolina + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03239470" }, { "nct_id": "NCT06251973", "title": "A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Esophageal Carcinoma", "Advanced Unresectable Gastric Adenocarcinoma", "Metastatic Gastric Cancer", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Esophageal Cancer", "Metastatic Esophageal Adenocarcinoma", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastric Carcinoma", "Unresectable Esophageal Cancer", "Unresectable Esophageal Adenocarcinoma", "Unresectable Gastric Carcinoma", "Unresectable Gastric Adenocarcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "AgenT-797", "type": "BIOLOGICAL" }, { "name": "Botensilimab", "type": "BIOLOGICAL" }, { "name": "Balstilimab", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2024-02-01", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-11-15T19:40:18.728Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06251973" }, { "nct_id": "NCT00087373", "title": "Vaccine Therapy in Treating Patients With Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "recombinant fowlpox-TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2004-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-11-15T19:40:18.728Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00087373" } ] }